PRAGUE, Czech Republic--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced that nearly 25 posters and symposia sponsored by the company will be presented at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Prague, Czech Republic. These presentations and symposia will cover five agents that are marketed or currently in development by Biogen Idec and its partners for the treatment of multiple sclerosis (MS). The two approved therapies for MS are TYSABRI®(natalizumab) and AVONEX® (Interferon beta-1a); and agents in development are BG-12 (dimethyl fumarate), daclizumab and RITUXAN® (rituximab).
